Having identified the broader picture, the text then begin to focus much more explicitly on a variety of HR policies and practices such as: recruitment and selection, legislation and equal opportunities, staff health and welfare and remuneration strategies in the industry. It initially sets the scene with a broad review of the evidence of HRM practice within the tourism and hospitality industries.
Myriad hrd how to#
Utilising existing human resource management (HRM) theory and practice, it contextualises it to the tourism and hospitality industries by looking at the specific employment practices of these industries, such as how to manage tour reps or working in the airline industry. Описание: Human Resource Management for the Hospitality and Tourism Industries 2nd Edition, takes an integrated look at HRM policies and practices in the tourism and hospitality industries. through a global strategic oncology collaboration launched in July 2017.Название: Human Resource Management for Hospitality and Tourism, 2 ed. Lynparza is being co-developed and co-commercialized by AstraZeneca and Merck & Co. Myriad has launched companion diagnostics collaborations with all four developers of PARP inhibitors. AstraZeneca is one of four PARP inhibitor developers, along with BeiGene, Clovis Oncology, and Tesaro. Patients are selected for therapy based on Myriad’s FDA-approved companion diagnostic. Lynparza is also indicated for adults with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. The first FDA-approved poly (ADP-ribose) polymerase (PARP) inhibitor upon its authorization by the FDA in 2014, Lynparza is indicated in part as a maintenance treatment for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. Since 2007, Myriad and AstraZeneca have carried out an ongoing collaboration to develop a novel companion diagnostic test to identify candidates for treatment with olaparib. In December 2014, Myriad won FDA approval for BRACAnalysis CDx, a BRCA1 and BRCA2 diagnostic test designed to identify patients with advanced ovarian cancer who are eligible for fourth-line treatment with Lynparza.īRACAnalysis CDx is Myriad’s first FDA-approved companion diagnostic and was the first-ever laboratory developed test approved by the FDA.
Myriad hrd plus#
“We are optimistic that m圜hoice HRD Plus will identify more women with ovarian cancer who could benefit from therapy with Lynparza than previous tests that only identify germline BRCA1/2 mutations,” Myriad CSO Jerry Lanchbury, Ph.D., said in a statement. m圜hoice HRD Plus is a composite of three proprietary technologies-loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions-and up to 90 other genes and molecular markers including microsatellite instability associated with DNA repair pathways. M圜hoice HRD Plus is a homologous recombination deficiency test designed to detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. Myriad said it will use m圜hoice HRD Plus to evaluate patients enrolled in an ongoing Phase III trial, with the goal of identifying cases with homologous recombination deficiencies (HRD). The value of the collaboration-an expanded research partnership with AstraZeneca-was not disclosed. Myriad Genetics said today that its m圜hoice HRD Plus test will be used by AstraZeneca in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with a combination of AZ’s Lynparza (olaparib) and the Genentech (Roche) cancer drug Avastin® (bevacizumab). Myriad Genetics' m圜hoice HRD Plus test will be used by AstraZeneca in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with a combination of AZ’s Lynparza® (olaparib) and the Genentech (Roche) cancer drug Avastin® (bevacizumab).
0 kommentar(er)
